Amgen Inc. (NASDAQ:AMGN) Shares Sold by AIMZ Investment Advisors LLC

AIMZ Investment Advisors LLC reduced its position in shares of Amgen Inc. (NASDAQ:AMGN) by 1.1% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 13,217 shares of the medical research company’s stock after selling 148 shares during the period. Amgen comprises approximately 1.2% of AIMZ Investment Advisors LLC’s holdings, making the stock its 27th largest holding. AIMZ Investment Advisors LLC’s holdings in Amgen were worth $3,445,000 at the end of the most recent quarter.

Other hedge funds have also recently added to or reduced their stakes in the company. AMF Tjanstepension AB increased its position in Amgen by 16.9% in the third quarter. AMF Tjanstepension AB now owns 120,389 shares of the medical research company’s stock worth $38,825,000 after buying an additional 17,387 shares during the period. Swedbank AB lifted its stake in Amgen by 1.1% in the 3rd quarter. Swedbank AB now owns 538,899 shares of the medical research company’s stock worth $173,639,000 after acquiring an additional 5,751 shares in the last quarter. Nicholas Hoffman & Company LLC. increased its stake in Amgen by 23.3% in the 3rd quarter. Nicholas Hoffman & Company LLC. now owns 1,033 shares of the medical research company’s stock valued at $333,000 after buying an additional 195 shares during the period. Diversify Wealth Management LLC increased its stake in shares of Amgen by 26.5% in the third quarter. Diversify Wealth Management LLC now owns 4,647 shares of the medical research company’s stock worth $1,463,000 after acquiring an additional 973 shares during the last quarter. Finally, Cornerstone Wealth Group LLC raised its holdings in shares of Amgen by 1.0% during the third quarter. Cornerstone Wealth Group LLC now owns 12,944 shares of the medical research company’s stock worth $4,171,000 after acquiring an additional 130 shares in the last quarter. Institutional investors and hedge funds own 76.50% of the company’s stock.

Analyst Ratings Changes

AMGN has been the subject of a number of recent research reports. Deutsche Bank Aktiengesellschaft decreased their price objective on shares of Amgen from $305.00 to $285.00 in a report on Wednesday, November 27th. Bank of America upped their price target on Amgen from $256.00 to $275.00 and gave the stock an “underperform” rating in a report on Thursday, February 6th. Piper Sandler Companies restated an “overweight” rating and issued a $310.00 price objective on shares of Amgen in a research note on Thursday, January 2nd. Wolfe Research started coverage on shares of Amgen in a research note on Friday, November 15th. They set a “peer perform” rating for the company. Finally, Royal Bank of Canada restated an “outperform” rating and issued a $324.00 price target on shares of Amgen in a research report on Friday, January 24th. Two investment analysts have rated the stock with a sell rating, ten have issued a hold rating, twelve have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, Amgen presently has an average rating of “Hold” and an average price target of $314.09.

Insider Buying and Selling

In related news, EVP Jonathan P. Graham sold 25,045 shares of the stock in a transaction that occurred on Friday, February 7th. The stock was sold at an average price of $293.12, for a total value of $7,341,190.40. Following the transaction, the executive vice president now owns 28,987 shares of the company’s stock, valued at $8,496,669.44. This represents a 46.35 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP David M. Reese sold 25,225 shares of the stock in a transaction dated Friday, February 21st. The shares were sold at an average price of $304.44, for a total transaction of $7,679,499.00. Following the sale, the executive vice president now directly owns 36,922 shares of the company’s stock, valued at approximately $11,240,533.68. The trade was a 40.59 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 69,341 shares of company stock worth $20,644,335. 0.69% of the stock is owned by corporate insiders.

Amgen Stock Down 0.2 %

Shares of NASDAQ:AMGN opened at $305.82 on Friday. The company has a current ratio of 1.26, a quick ratio of 0.95 and a debt-to-equity ratio of 9.62. The stock’s 50-day moving average price is $279.97 and its 200-day moving average price is $300.24. The stock has a market capitalization of $164.29 billion, a P/E ratio of 40.51, a price-to-earnings-growth ratio of 2.63 and a beta of 0.56. Amgen Inc. has a 12-month low of $253.30 and a 12-month high of $346.85.

Amgen (NASDAQ:AMGN) last released its quarterly earnings results on Tuesday, February 4th. The medical research company reported $5.31 earnings per share for the quarter, beating the consensus estimate of $5.04 by $0.27. Amgen had a return on equity of 176.32% and a net margin of 12.24%. On average, equities analysts anticipate that Amgen Inc. will post 20.62 earnings per share for the current year.

Amgen Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, March 7th. Investors of record on Friday, February 14th will be issued a $2.38 dividend. The ex-dividend date of this dividend is Friday, February 14th. This represents a $9.52 annualized dividend and a yield of 3.11%. This is an increase from Amgen’s previous quarterly dividend of $2.25. Amgen’s dividend payout ratio is currently 126.09%.

About Amgen

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.